Sotera Health (SHC) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Sotera Health published the results on November 3, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Sotera Health reports EPS two ways: GAAP, under the accounting rules every US filer follows, and Adjusted EPS, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Sotera Health attributes Nordion's Q3 2026 revenue decline to the expected timing of Cobalt-60 (Co-60) harvest schedules; over the first nine months Nordion revenue was up 6.1%.
• Sotera Health's adjusted results exclude professional fees tied to its ethylene oxide (EO) sterilization facilities, $11.7 million in Q3 2026, along with EO litigation settlements when they occur.

Source: Sotera Health Q3 2026 results, November 3, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Sotera Health splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Sotera Health's Sterigenics revenue was $209 million in Q3 2026, up 9% from $193 million in Q3 2025, 64% of total revenue.
• Sotera Health's Nordion revenue was $55.0 million in Q3 2026, down 12% from $62.8 million in Q3 2025, 17% of total revenue.
• Sotera Health's Nelson Labs revenue was $60.6 million in Q3 2026, up 9% from $55.7 million in Q3 2025, 19% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Sotera Health said:

“Net revenues in the range of $1.233 billion to $1.250 billion, representing constant currency growth of 5.25% to 6.75%.”

“Adjusted EBITDA in the range of $632 million to $641 million, representing constant currency growth of 5.75% to 7.25%.”

“Adjusted EPS range remains in the range of $0.95 to $1.01.”

“Capital expenditures remain in the range of $200 million to $225 million.”

Source: Sotera Health Q3 2026 release, Nov 3, 2026.

This is the company's own guidance as of Nov 3, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the SHC forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

Total net revenues and GAAP diluted EPS, each as first reported in that quarter's release.

We do not hold a confirmed date for Sotera Health's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 3, 2026

Sotera Health's net revenues rose 4.4% to $324.9 million in Q3 2026, the same growth on an as-reported and constant currency basis. Sterigenics, its outsourced sterilization business, brought in $209.3 million, up 8.5% (8.2% in constant currency), on pricing, improved volume and mix and a foreign currency benefit. (Sotera Health Q3 2026 release, Nov 3, 2026)

Nordion supplies Cobalt-60, the radioactive isotope used in gamma sterilization, and gamma irradiation systems. Its revenue fell 12.4% to $55.0 million because of the expected timing of Co-60 harvest schedules, partly offset by pricing; for the first nine months Nordion revenue was up 6.1% at $146.2 million. (Sotera Health Q3 2026 release, Nov 3, 2026; Sotera Health Form 10-K, 2025, Feb 24, 2026)

Nelson Labs, the lab testing and advisory business, grew revenue 8.8% to $60.6 million, or 9.2% in constant currency, on volume, mix and pricing. Sotera Health completed a new Nelson Labs Annex-1 compliant cleanroom in the quarter. (Sotera Health Q3 2026 release, Nov 3, 2026)

Sotera Health's revenue is spread across many customers. The 10-K says no single customer accounted for more than 10% of total revenues, more than 90% of Sterigenics' 2025 revenues came from customers under multi-year contracts, and Sterigenics operates 48 facilities in 13 countries. (Sotera Health Form 10-K, 2025, Feb 24, 2026)

Sotera Health's GAAP diluted EPS was $0.20 in Q3 2026, against $0.17, on net income of $58.4 million. Adjusted EPS was $0.29, up from $0.26. Adjusted Net Income of $82.5 million adds back professional services relating to EO sterilization facilities ($11.7 million), share-based compensation ($7.8 million), amortization of intangible assets ($5.5 million) and business optimization expenses ($2.4 million), less related tax effects. (Sotera Health Q3 2026 release, Nov 3, 2026)

Interest expense, net fell to $34.1 million from $39.1 million. The effective tax rate was 30.3%, against 33.6% a year earlier. Diluted weighted average shares were 289,217 thousand, against 286,745 thousand. (Sotera Health Q3 2026 release, Nov 3, 2026; Sotera Health Form 10-Q, Q3 2026, Nov 3, 2026)

Sotera Health still faces EO lawsuits. As of October 29, 2026, about 550 personal injury and wrongful death claims tied to Sterigenics' Atlanta facility were assigned to a single judge in Cobb County, Georgia, and initial trials in the cases over its Vernon facilities are scheduled for January and April 2027. (Sotera Health Form 10-Q, Q3 2026, Nov 3, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Sotera Health gives full-year guidance in its release and reaffirmed its 2026 constant currency outlook: net revenues of $1.233 billion to $1.250 billion (growth of 5.25% to 6.75%), Adjusted EBITDA of $632 million to $641 million, and Adjusted EPS of $0.95 to $1.01. It cut the expected foreign currency benefit to 70 basis points from 100 and narrowed interest expense to $137 million to $140 million. (Sotera Health Q3 2026 release, Nov 3, 2026)

A consensus figure is the average of the models published by the analysts who cover Sotera Health, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Sotera Health's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning SHC is on is SHC a buy or a sell?, what analysts expect next is on the SHC forecast, and what the company does is on the Sotera Health (SHC) stock page.

Every number on this page can be traced to a document Sotera Health published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.